Unity Biotechnology, Inc. (NASDAQ:UBX) Shares Sold by Renaissance Technologies LLC

Renaissance Technologies LLC decreased its holdings in shares of Unity Biotechnology, Inc. (NASDAQ:UBX) by 39.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 64,582 shares of the company’s stock after selling 42,359 shares during the quarter. Renaissance Technologies LLC’s holdings in Unity Biotechnology were worth $87,000 at the end of the most recent quarter.

Analysts Set New Price Targets

Several research firms have issued reports on UBX. HC Wainwright reissued a “buy” rating and set a $8.00 target price on shares of Unity Biotechnology in a research note on Thursday, August 8th. Rodman & Renshaw assumed coverage on Unity Biotechnology in a research note on Thursday, August 22nd. They issued a “buy” rating and a $8.00 price objective for the company.

Unity Biotechnology Trading Down 2.7 %

Shares of NASDAQ UBX opened at $1.46 on Tuesday. Unity Biotechnology, Inc. has a twelve month low of $1.22 and a twelve month high of $2.26. The stock has a fifty day simple moving average of $1.48 and a 200-day simple moving average of $1.49. The stock has a market capitalization of $24.51 million, a PE ratio of -0.58 and a beta of 0.83.

Unity Biotechnology (NASDAQ:UBX) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.31) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.15. On average, equities analysts predict that Unity Biotechnology, Inc. will post -1.49 earnings per share for the current year.

Unity Biotechnology Company Profile

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.